Lymphoma response to chimeric antigen receptor T cell therapy is driven by endogenous tumor-reactive CD8⁺ T cells
Bachisio Ziccheddu, Constanza Savid-Frontera, Venu V.G. Saralamma, Chandler Gatenbee, Abdessamad A. Youssfi, Monika Chojnacka, Meghan A. Menges, Luis Cuadrado-Delgado, Michael A. Durante, John E. Mullinax, Keyla Reid, Julieta Abraham Miranda, Salvatore Corallo, Emily Merritt, W Greg Sawyer, , Frederick Lundry Locke
This study shows that durable CAR-T therapy in lymphoma requires cooperation with endogenous CD8 T cells, and tumors lacking MHC class I or CD58 resist treatment.
bioRxiv · Oct 27, 2026 · PreprintCancer Biology